Aclacinomycin A (CAS 57576-44-0)
See product citations (10)
QUICK LINKS
Aclacinomycin A (Aclarubicin), an anthracycline, is a compound of interest in biochemical research due to its interaction with nucleic acids. It is known to intercalate into DNA, disrupting the synthesis of RNA and DNA by inhibiting the action of topoisomerase II, an enzyme for DNA replication and repair. Research involving Aclacinomycin A focuses on its ability to interfere with the cell cycle, particularly in the context of its binding affinity to DNA and the subsequent biological effects on cellular replication processes. This interaction is key in studies that aim to understand the mechanisms of action of agents that target topoisomerase II. Furthermore, the compound is used to probe the structure-function relationships in DNA and the dynamics of DNA intercalation. Studies utilizing Aclacinomycin A contribute to the field of molecular biology by providing insights into the regulation of gene expression and the integrity of genetic material under the influence of DNA-binding agents.
Aclacinomycin A (CAS 57576-44-0) References
- Characterization of mutations in aclacinomycin A-non-producing Streptomyces galilaeus strains with altered glycosylation patterns. | Räty, K., et al. 2002. Microbiology (Reading). 148: 3375-3384. PMID: 12427929
- Inhibition of different steps of the ubiquitin system by cisplatin and aclarubicin. | Isoe, T., et al. 1992. Biochim Biophys Acta. 1117: 131-5. PMID: 1326334
- AknK is an L-2-deoxyfucosyltransferase in the biosynthesis of the anthracycline aclacinomycin A. | Lu, W., et al. 2004. Biochemistry. 43: 4548-58. PMID: 15078101
- Antagonistic effect of aclarubicin on daunorubicin-induced cytotoxicity in human small cell lung cancer cells: relationship to DNA integrity and topoisomerase II. | Jensen, PB., et al. 1991. Cancer Res. 51: 5093-9. PMID: 1655244
- Characterization of rhodosaminyl transfer by the AknS/AknT glycosylation complex and its use in reconstituting the biosynthetic pathway of aclacinomycin A. | Leimkuhler, C., et al. 2007. J Am Chem Soc. 129: 10546-50. PMID: 17685523
- Aclacinomycin A sensitizes K562 chronic myeloid leukemia cells to imatinib through p38MAPK-mediated erythroid differentiation. | Lee, YL., et al. 2013. PLoS One. 8: e61939. PMID: 23613979
- Drug-induced histone eviction from open chromatin contributes to the chemotherapeutic effects of doxorubicin. | Pang, B., et al. 2013. Nat Commun. 4: 1908. PMID: 23715267
- Low-dose arsenic trioxide combined with aclacinomycin A synergistically enhances the cytotoxic effect on human acute myelogenous leukemia cell lines by induction of apoptosis. | Ye, Y., et al. 2015. Leuk Lymphoma. 56: 3159-67. PMID: 25739941
- Self-assembled albumin nanoparticles as a nanocarrier for aclacinomycin A. | Gong, G., et al. 2016. Nanotechnology. 27: 465602. PMID: 27749275
- Activin A downregulates the CD69-MT2A axis via p38MAPK to induce erythroid differentiation that sensitizes BCR-ABL-positive cells to imatinib. | Chen, CW., et al. 2022. Exp Cell Res. 417: 113219. PMID: 35643179
- Isolation and characterization of aclacinomycin A-non-producing Streptomyces galilaeus (ATCC 31615) mutants. | Ylihonko, K., et al. 1994. Microbiology (Reading). 140 (Pt 6): 1359-65. PMID: 8081501
- The antitumor drug aclacinomycin A, which inhibits the degradation of ubiquitinated proteins, shows selectivity for the chymotrypsin-like activity of the bovine pituitary 20 S proteasome. | Figueiredo-Pereira, ME., et al. 1996. J Biol Chem. 271: 16455-9. PMID: 8663210
- Toxicity and antiproliferative effect of aclacinomycin A on RPE cells in vitro. | Schmidt, JF. and Loeffler, KU. 1996. Curr Eye Res. 15: 1112-6. PMID: 8950505
- Aclacinomycin A stabilizes topoisomerase I covalent complexes. | Nitiss, JL., et al. 1997. Cancer Res. 57: 4564-9. PMID: 9377570
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Aclacinomycin A, 5 mg | sc-200160 | 5 mg | $129.00 |